Distribution of company announcements to the professional platforms, finance portals and syndication of important corporate news to a wide variety of news aggregators and financial news systems.
Biotec Pharmacon ASA (OSL:BIOTEC) Dr. Rohmann is a MD by training and has a Ph.D. in experimental cardiology. He is joining the company from Novartis Pharma AG, where he, as part of the Global Business Development & Licensing Team, was heading up the company's Venture Capital Fund activities.
Dr. Rohmann brings to Biotec Pharmacon more than fifteen years of experience from different pharmaceutical/biotechnology businesses, with extensive exposure to the drug development process, having filled senior management positions in the fields of research, marketing, management and last, but not least, business development.
Throughout the 1990's Dr. Rohmann spent close to ten years with the pharmaceutical company Merck KGaA in different management positions, finally serving as Global Head Strategic Marketing Oncology, with responsibility for global oncology marketing and sales activities. Leaving Merck KGaA Dr. Rohmann spent the next five years working with a few start-up biotechnology companies in Chief Executive Officer positions, involved in a variety of business development activities, until he joined the Global Business Development & Licensing Team at Novartis Pharma AG.
"We were obsessed by finding a candidate with solid skills, training and global pharmaceutical experience", says Dr. Lars Viksmoen, CEO of Biotec Pharmacon ASA. "At no point were we willing to compromise on quality. In bringing significant business development experience to Biotec Pharmacon ASA, Dr. Rohmann will play a major role in further developing and implementing the company's partner strategy", says Dr. Viksmoen. "I'm impressed with what Biotec Pharmacon has achieved over the last couple of years and am ready to support a clinical development program for which I've high hopes", says Dr. Sven Rohmann.
Dr. Rohmann's appointment is effective as of October 1.
For questions and/or supplemental information, please contact: CEO Lars Viksmoen, phone +47 40 62 08 70
About Biotec Pharmacon ASA Biotec Pharmacon ASA develops pharmaceutical product candidates for the treatment of immune related diseases. The company's bioactive SBG substance strengthens the ability of the immune system to repair skin and mucous membranes, and to attack and destroy cancerous cells when combined with monoclonal antibodies. The company has made considerable progress in its pharmaceutical development programme and expects to have four phase III studies running in parallel within two targeted disease areas by the end of the year. The company's goal is to seek marketing authorization for SBG for the treatment of diabetic ulcers and oral mucositis by mid 2010. The company's clinical development programme also includes immunotherapy of cancer, currently in phase I/II. Additionally, Biotec Pharmacon ASA develops, produces and markets non-pharmaceutical health and diagnostic products. Biotec Pharmacon currently employs 52 people, and has offices in Tromsø, Oslo and Long Beach, California.
